



Biocept Inc.
Investor Relations Department
5810 Nancy Ridge Drive
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: BIOC

| | |
|---------------|----------------------------|
| Last Trade: | 1.42 |
| Trade Time: | 4:00 PM ET Jun 23, 2017 |
| Change: | 0.01 (+0.709%) |
| Day Range | 1.32 - 1.45 |
| 52-Week Range | 0.74 - 3.39 |
| Volume | 443,570 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 21, 2017

[Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing](#)

May 22, 2017

[Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood](#)

May 18, 2017

[Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign](#)

May 11, 2017

[Biocept Reports First Quarter 2017 Financial Results](#)

May 10, 2017

[The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 28, 2017

[Annual Report \(10-K\)](#)

Mar 30, 2017

[Proxy Statement \(DEF 14A\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)

Nov 10, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)